tremelimumab

Overview

Tremelimumab is a human anti-CTLA-4 monoclonal antibody targeting CTLA4. It is evaluated as an immune checkpoint inhibitor, notably in combination with durvalumab for hepatocellular carcinoma (HCC).

Evidence in the corpus

• Phase II tremelimumab monotherapy in HCC: ORR 17.6% in 20 patients PMID:24798001.
• Durvalumab + tremelimumab combination (anti-PD-L1 + anti-CTLA-4) under evaluation in HCC (NCT03298451) as part of dual checkpoint blockade strategies PMID:24798001.
• Studied in 5 metastatic melanoma (SKCM) patients as anti-CTLA-4 agent alongside ipilimumab; high tumor mutational load and a shared tetrapeptide neoantigen signature in responders were significantly associated with long-term clinical benefit PMID:25409260
• Authors advocate considering combination checkpoint blockade including anti-CTLA4 agents such as tremelimumab for MSI-H metastatic EGC; MSI-H tumors had 4/9 (44%) carrying likely deleterious B2M alterations but some still responded to checkpoint blockade PMID:29122777

Resistance mechanisms

Cancer types (linked)

• HCC

Sources

This page was processed by crosslinker on 2026-05-14. - PMID:25409260

This page was processed by crosslinker on 2026-05-14. - PMID:29122777

This page was processed by wiki-cli on 2026-05-15.